Home Health & Home Care M&A · April 2026 · 10-Minute Read

In April 2026, federal regulators suspended Medicare payments to 23 home health organizations and 447 hospices in a coordinated fraud action centered on California, citing more than $600 million in alleged fraudulent billing. Days later, a Congressional witness testified that organized fraud is now migrating from hospice to home health as hospice enforcement tightens. If you own a clean home health, home healthcare, home care, or senior care agency, the question on your kitchen table tonight is simple: does this make my agency more valuable, or less?

The honest answer, as of April 2026: if your books are clean, your OASIS submissions reconcile to your claims, your PEPPER outliers are explainable, your 36-month rule status is clear, and your caregiver retention holds this is the strongest seller’s market for clean home health and senior care in five years. The California crackdown isn’t a reason to wait. For documentably clean operators, it’s the reason to move now, before deal pipelines clog and the diligence bar ratchets even higher.

This guide is built for you the home health, home healthcare, home care, or senior care agency owner weighing a valuation, an exit, or a recapitalization in 2026. We will cover what your agency is actually worth in today’s market, why the California fraud reset and the hospice-to-home-health enforcement migration are reshaping buyer behavior, the seven-step process Vallexa Advisors uses to sell home health and home care businesses confidentially, and the specific things you can do in the next 90 days to widen the gap between your sale price and the price your less-prepared neighbor will get.

What the April 2026 California crackdown means for home health and senior care

The short answer: Federal regulators just delivered the largest coordinated home-based-care payment-suspension action in Medicare history, with the home health side of the action concentrated in California. Buyers are sharpening diligence in response, and the gap between what a clean home health agency will sell for and what a problem agency will sell for is widening fast.

According to Home Health Care News, CMS, the OIG, and the UPIC contractors coordinated the simultaneous suspension of Medicare payments at 23 home health organizations and 447 hospices, with the home health portion of the action heavily concentrated in California. The total alleged fraud exposure exceeds $600 million. That single number is reframing the M&A market buyers’ Quality of Earnings teams are now flagging the same indicators that triggered the suspensions and walking away from any deal where those indicators appear.

For California operators specifically, the crackdown changes diligence in three measurable ways. First, buyers now expect a California-specific fraud-risk attestation not just a generic compliance certification. Second, R&W insurance carriers writing policies on California home health deals are excluding more risks and requiring higher retentions. Third, several PE-backed platforms have temporarily paused new California deal flow until they can re-baseline their California diligence playbook against the suspended-organization patterns. Clean California agencies are still trading but with longer LOI-to-close timelines and tighter working-capital pegs.

The California crackdown isn’t a market signal to wait. It’s a market signal to get clean, document everything, and get to market before the buyer pool narrows further.

Why fraud is migrating from hospice to home health and what buyers are doing about it

Short answer: A Congressional witness testified in April 2026 that bad actors who entered hospice in 2018–2023 are now rotating into home health as hospice enforcement tightens. CMS, the OIG, and MedPAC are responding by widening the home health enforcement net more PEPPER scrutiny, tighter UPIC sampling, expanded provisional periods, and a sharper focus on referral-source kickback structures. Buyers, not surprisingly, are following the regulators.

A second HHCN report on Congressional testimony in April 2026 warned that fraud actors are following the path of least resistance into home health, particularly in markets where state oversight is light or where private-pay home care licensure can be used as a beachhead before applying for Medicare certification. For owners considering an exit, this matters: buyers want to see clean separation between Medicare-certified home health and any private-duty home care or senior care lines, separate compliance programs, clean intercompany economics, and zero referral-source overlap with operators that have been suspended or settled.

And a third HHCN piece on the expanding enforcement net documents how scrutiny is broadening from agencies themselves to billing companies, marketers, medical directors, and referral-source kickback structures across the full at-home-care continuum. Translation for owners considering an exit: pre-LOI fraud-risk attestations are now standard, and any documentation gap in those areas can stall or kill a deal that should have closed in 90 days.

The buyer response is uniform across PE-backed platforms, regional consolidators, and health-system arms: tighter pre-LOI attestations, deeper PEPPER analysis, more granular OASIS-to-claim reconciliation, expanded sanctions and exclusions screening (NPI-level, not just entity-level), and California-specific risk add-ons where applicable. None of this is a problem for a clean operator with documentation. All of it is a deal-killer for an operator who has been running the books loosely.

What is my home health or home care agency worth in 2026?

Short answer: Most clean independent Medicare-certified home health agencies in April 2026 are trading at 5x–7x adjusted EBITDA, or roughly 0.6x–1.1x trailing revenue. Premium multi-state platforms with $20M+ revenue can clear 7x–9x and occasionally higher. Private-pay home care and senior care businesses (companion care, personal care, non-skilled) typically trade at 3x–6x adjusted EBITDA, depending on caregiver retention, payer mix, and franchise vs. independent. Audit-flagged or PDGM-loser agencies often sell at 2x–4x or in asset-only structures and many are unsalable until cleared.

The longer answer: home health and home care valuation is not a single multiple. It is a stack of factors, each of which moves your number up or down. The same $3M-EBITDA agency can be worth $15M to one buyer and $24M to another based on the items below.

Home health valuation multiples by scale tier (April 2026)

Profile	Trailing revenue	Adjusted EBITDA Multiple	Revenue Multiple
Sub-scale Medicare-certified	< $3M	3.5x – 5x	0.4x – 0.7x
Established Medicare-certified	$3M – $10M	5x – 6.5x	0.6x – 0.95x
Regional standout (multi-county)	$10M – $25M	6x – 8x	0.85x – 1.1x
Multi-state platform	$25M+	7.5x – 9x+	1.0x – 1.4x
Private-pay home care / senior care	Any	3x – 6x	0.3x – 0.8x
UPIC / PEPPER-flagged / fraud-adjacent	Any	2x – 4x or asset deal	0.15x – 0.4x

What actually moves your home health or home care agency’s multiple

• Episode volume and trajectory. Buyers pay for slope, not just size. An agency growing 10–15% YoY usually beats a flat agency of the same scale.
• PDGM case-mix weight (CMW). A higher CMW tied to clinically appropriate clinical groupings, comorbidity adjustments, and functional impairment scoring drives reimbursement per period and multiple expansion.
• LUPA rate. A LUPA rate sitting meaningfully below your peer group is a real source of multiple expansion. A high LUPA rate signals operational drag and weakens your number.
• Recertification rate. Industry norm is roughly 30–40%. Sustained recertification rates outside that band high or low invite buyer scrutiny.
• Payer mix. Medicare FFS, Medicare Advantage, Medicaid, managed care, and private-pay each carry different yield and risk profiles. MA growth above peer norms helps; heavy MA concentration with poor contract terms hurts.
• HHVBP and Quality of Patient Care / Patient Survey star ratings. The Home Health Value-Based Purchasing program is now nationwide and meaningfully reshapes reimbursement. Strong star ratings are valuation rocket fuel; sub-3-star ratings are a discount lever.
• OASIS accuracy. Buyers now reconcile a sample of OASIS-E submissions to claims and to documentation. Mismatches stall deals.
• PEPPER outliers. A clean PEPPER report with explanations for any flagged metrics is now table stakes for a premium multiple.
• Caregiver retention & clinician fill rate. RN and aide turnover above peer median is a multiple compressor. Strong retention and a documented hiring engine expand it.
• Referral concentration. No single referral source above 15–20% is the gold standard. Heavy concentration on one hospital or one health system triggers indemnification reserves.
• Compliance posture. Confirmed 36-month rule eligibility, no active UPIC review, clean exclusions screening, documented marketer compensation FMV these are now pre-LOI attestations.
• For private-pay / senior care: Caregiver retention, average client tenure, hours per client per week, payer mix (long-term care insurance, VA Aid & Attendance, private-pay), and franchise vs. independent all move the multiple meaningfully.

The “flight to quality” thesis why clean home health and senior care operators win in 2026

Short answer: Every home-based-care fraud crackdown cycle since 2018 has produced the same M&A pattern. Buyers retreat for one to two quarters, then return with tighter diligence and a higher willingness to pay for clean, audited operators. The April 2026 cycle is the strongest version of this dynamic yet and it has now reached home health and the private-pay home care/senior care segment.

Three forces are pushing the same direction: PE-backed platforms have capital they need to deploy, the California crackdown just took dozens of competitors off the buyer’s shopping list, and Medicare Advantage plans are increasingly building captive home-based-care delivery, which adds a new buyer class with strategic urgency. For a clean independent in a desirable geography, this is the most concentrated demand for clean home health assets we have seen in five years.

That doesn’t mean it is suddenly easy. Diligence cycles are slower. Working-capital pegs are tighter. R&W insurance carriers are excluding more risks than they did a year ago. But for an owner with a clean operation and good documentation, this is a market environment where being prepared is worth real money and being unprepared costs real money.

How to sell a home health or home care agency: the 7-step Vallexa process

Short answer: Engage a healthcare-only M&A advisor, normalize EBITDA, attest compliance, build the CIM, run a confidential auction to a vetted buyer network, negotiate the LOI, and close the CHOW. Plan for 6–9 months end to end for Medicare-certified home health, 4–6 months for private-pay senior care without a CHOW.

1. Build a complimentary, accurate valuation. Start with a no-cost confidential valuation from a healthcare-only advisor. The right number is built on adjusted EBITDA, episode volume, PDGM case mix, LUPA rate, recertification rate, payer mix, HHVBP/STAR performance, and caregiver retention not on a generic “industry multiple.”
2. Normalize EBITDA and prep the data room. Document add-backs (owner comp, one-time legal, M&A advisory, non-recurring marketing, personal expenses). Prepare three years of statements, a working-capital schedule, and a CapEx history. Assemble the data room before any buyer is contacted.
3. Run a pre-LOI compliance attestation. Confirm CMS 36-month rule eligibility, document UPIC/MAC/RAC review history, verify OASIS-E submission accuracy, run a PEPPER outlier review, produce clean OIG/SAM exclusions screening, and review your marketer and physician arrangements for FMV and Stark/AKS compliance.
4. Build the Confidential Information Memorandum (CIM). Tell the growth and market story. Quantify the buyer thesis. Document the post-close transition plan including how long you will stay, what “help” looks like, and what the earnout structure should reward.
5. Run a confidential auction to a vetted buyer network. Approach 25–75 qualified buyers under NDA. Collect Indications of Interest (IOIs). Shortlist for management meetings. Vallexa’s vetted network covers PE-backed home-based-care platforms, regional consolidators, hospital and health-system home-health arms, payviders and MA plans, and independent strategics plus franchisors and PE-backed multi-brand platforms on the senior care side.
6. Negotiate the LOI and select the buyer. Compare price, structure, earnout, working-capital peg, escrow holdback, indemnification, R&W insurance, and post-close terms. The highest headline price is rarely the highest net price.
7. Close diligence and complete the CHOW. Coordinate Quality of Earnings, legal diligence, and the Medicare 855A Change of Ownership filing through definitive agreements and close. Plan for 60–120 days on the CHOW alone and watch the 36-month rule like a hawk.

This is the same seven-step process Vallexa Advisors runs for every home health and home care client. We have refined it over more than a decade of home-based-care transactions, and we update it every quarter as the diligence environment evolves.

Who buys home health and home care agencies in 2026?

Short answer: The 2026 home health and home care buyer landscape has five primary archetypes for Medicare-certified agencies and three primary archetypes for private-pay home care / senior care. Each has a different pricing logic and a different post-close lifestyle for you.

Buyers for Medicare-certified home health

Buyer type	What they pay for	Typical structure	Your post-close life
PE-backed home-based-care platform	Scale, episode growth, leadership depth, geographic fit	Cash + earnout + rollover equity	2–4 year transition; possible second-bite at recap
Regional consolidator	State density, referral relationships, license	Cash + modest earnout	6–18 month transition
Hospital / health-system home-health arm	Continuum-of-care, market share, employed referral capture	Cash + retention	1–3 year transition; integration leadership role available
Payvider / Medicare Advantage plan	Captive care delivery, MLR control, member experience	Cash + retention	1–2 year transition
Independent strategic	Single-state add-on, complementary catchment	Cash + small earnout	3–12 month transition

Buyers for private-pay home care / senior care

Buyer type	What they pay for	Typical structure	Your post-close life
PE-backed multi-brand senior care platform	Hours, caregiver retention, geographic density	Cash + earnout + rollover	2–3 year transition
Franchisor	Compatible operating model, territory fit, owner stay-on	Cash + transition support	6–24 month transition
Regional independent consolidator	Hours, payer relationships, market share	Cash + modest earnout	3–12 month transition

The CHOW timeline, the 36-month rule, and why your sale takes 6–9 months

Short answer: A typical Medicare-certified home health sale runs 6–9 months from advisor engagement to close. The Medicare 855A CHOW filing alone takes 60–120 days. Add 60–90 days when there is active UPIC review, complex corporate structure, or multi-state licensure. Private-pay home care and senior care without Medicare certification can close in 4–6 months.

• Months 1–2: Valuation, EBITDA normalization, data room build, CIM drafting, pre-LOI compliance attestation (including 36-month rule check and PEPPER outlier review).
• Months 3–4: Confidential buyer outreach, IOIs received, management meetings, LOI negotiation and selection.
• Months 5–6: Quality of Earnings, legal diligence, definitive agreement negotiation, 855A CHOW filing initiated.
• Months 7–9: CMS regional office processing, state license transfers, working-capital peg true-up, escrow setup, close.

The CMS 36-month rule, in plain English

The 36-month rule prohibits a Medicare-certified home health agency from undergoing a change of majority ownership within 36 months of either initial Medicare certification or a prior change of majority ownership. If you trip the rule, the buyer loses your billing privileges and has to apply for new certification a process that takes a year or more and effectively kills the deal. That is why Vallexa runs a 36-month eligibility check inside week one of every home health engagement, before we touch the data room.

The biggest variables on the back end are regulatory: a clean compliance file shaves weeks; an open audit adds months. The second biggest is corporate hygiene — minute books, cap tables, lease estoppels, contract assignability. Get these right early and the back end of the timeline runs on rails.

Your 90-day pre-sale readiness plan

You don’t need to know whether you’ll sell in 2026 to start preparing. The work below pays off whether you sell next quarter or hold for three more years and it’s the difference between a 5x deal and a 7x deal.

Days 1–30 Get the numbers right

• Pull three years of financial statements and reconcile to the G/L and Medicare cost reports.
• Build a normalized EBITDA worksheet with documented add-backs.
• Run a payer-mix analysis (Medicare FFS / MA / Medicaid / private) by month, by branch, for the trailing 24 months.
• Build episode-volume, PDGM case-mix-weight, and LUPA-rate trend lines for the trailing 24 months.
• Pull your latest PEPPER report and document explanations for any flagged metrics.

Days 31–60 Get the compliance file clean

• Confirm 36-month rule eligibility for every CCN and licensed location.
• Pull last three surveys with PoCs and close-out letters.
• Document UPIC, ZPIC, RAC, and MAC review history. Address any open items.
• Audit OASIS-E submissions for accuracy. Reconcile a sample to claims and clinical documentation.
• Refresh your Code of Conduct, exclusions screening, and marketer compensation FMV documentation.
• Run a sanctions/exclusions screen at the NPI level not just the entity level.

Days 61–90 Get advisor-ready

• Engage a healthcare-only M&A advisor for a confidential valuation.
• Build the data room outline. Identify what’s missing and assign owners.
• Draft your post-close transition plan: 0, 6, 12, or 24 months and what “help” looks like.
• Build a net-proceeds model with your CPA so the headline number translates to a real number.
• For dual-line operators (home health + private-duty home care): document clean separation, separate compliance programs, and clean intercompany economics.

For the full 27-point version, download the Home Health & Home Care Pre-Sale Readiness Checklist below.

Frequently asked questions about selling a home health or home care agency in 2026

How are home health agencies valued in 2026?

As of April 2026, Medicare-certified home health agencies typically sell for 5x–7x adjusted EBITDA or 0.6x–1.1x trailing revenue. Premium multi-state platforms can clear 7x–9x and occasionally higher. Private-pay home care and senior care businesses typically trade at 3x–6x adjusted EBITDA. See the multiples table above for ranges by scale tier.

Will the April 2026 California crackdown hurt my home health agency’s sale price?

For clean operators, the suspension of 23 home health organizations and 447 hospices is more likely to lift your price than lower it. Buyers are paying measurable premiums for documentably clean books while pulling back from anything with PEPPER outliers, OASIS accuracy issues, or California-specific footprint risk. This is the strongest “flight to quality” window for home health and senior care M&A in five years.

How long does it take to sell a home health agency?

Plan for 6–9 months from advisor engagement to close for Medicare-certified home health. The Medicare 855A CHOW filing alone takes 60–120 days. Private-pay home care and senior care without Medicare certification can close in 4–6 months.

Can I sell my home health agency during a UPIC, ZPIC, or RAC review?

Yes, but the buyer pool narrows and structures change. Buyers will require disclosure, escrow holdbacks, and often an indemnification reserve. Some PE platforms will pause until the review closes; strategics with strong compliance functions may proceed with appropriate protections. Engage advisor and counsel early the right answer depends on the audit type, severity, and stage.

Who buys home health and home care agencies in 2026?

The 2026 buyer landscape includes PE-backed home-based-care platforms, regional consolidators, hospital and health-system home-health arms, payviders and Medicare Advantage plans, and independent strategics. For private-pay home care and senior care, franchisors and PE-backed multi-brand platforms have re-entered aggressively. Vallexa Advisors maintains a vetted, NDA-bound buyer network across all categories.

What is the CMS 36-month rule and why does it matter?

The 36-month rule prohibits a Medicare-certified home health agency from undergoing a change of majority ownership within 36 months of initial certification or a prior change of majority ownership. Trip the rule and the buyer must obtain new Medicare certification effectively a deal-killer. Confirming 36-month eligibility is now a standard pre-LOI attestation in home health diligence.

Do I need an M&A advisor to sell my home health or senior care agency?

You can sell without one, but you will almost always leave 1x–2x EBITDA on the table. A healthcare-only M&A advisor runs a confidential auction across a vetted buyer network, normalizes EBITDA, builds the data room, manages the CHOW, and protects the relationship with your caregivers and referral sources. At Vallexa Advisors, fees are 100% success-based you pay only at close.

What is my home health or home care agency worth?

Your agency’s value is a function of normalized EBITDA, episode volume, PDGM case mix, LUPA rate, recertification rate, payer mix, HHVBP and STAR ratings, caregiver retention, and referral concentration. The fastest path to a credible answer is a complimentary confidential valuation from Vallexa Advisors, built on the same model we apply to live transactions.

Is my home health or senior care agency too small to sell?

Probably not. Vallexa regularly closes single-branch home health agencies with $2M–$5M in revenue and private-pay senior care businesses with $1.5M+ in revenue, particularly in geographies attractive to regional consolidators and franchisors. Below those thresholds, the buyer pool narrows and asset-only structures become more common but a sale is almost always still possible.

Vallexa Advisors home health & home care resources

• How to sell a home health or hospice agency
• 2026 Home Health & Hospice Valuation Multiples Report (U.S. market)
• Home health & hospice valuation tools for business owners
• Hospice valuation methodology (companion post)
• Current Vallexa home health, home care, and hospice listings
• Healthcare industries Vallexa serves
• Meet the Vallexa Advisors team
• Contact Vallexa Advisors

---

About the author

Jason Atty is Managing Director at Vallexa Advisors, a healthcare-only M&A firm specializing in home health, home care, hospice, and behavioral health transactions. Jason brings 18+ years of healthcare M&A experience advising owners on confidential sale processes, valuation, and post-close transitions. Vallexa runs a confidential process built on a vetted national buyer network, with 100% success-based fees.

Sources & further reading

• Home Health Care News — Feds Suspend 23 Home Health Orgs, 447 Hospices Over $600M Medicare Fraud (April 2026)
• Home Health Care News — Fraud Migrating From Hospice to Home Health, Witness Warns Congress (April 2026)
• Home Health Care News — Hospice Fraud Trends Highlight Risk for At-Home Care Providers in Expanding Enforcement Net (April 2026)
• CMS — Home Health PPS & PDGM
• CMS — Home Health Quality Reporting Program (incl. HHVBP)
• CMS — Provider Enrollment (855A & Change of Ownership)
• HHS Office of Inspector General
• MedPAC — Medicare Payment Advisory Commission

This article is published for informational purposes only and does not constitute legal, tax, accounting, or investment advice. Every transaction is unique. Engage qualified counsel and a CPA before making material decisions. Last updated April 28, 2026.

Estimated reading time: 18 minutes

Selling Your Hospice in 2026: What the Crackdown Means for Valuation, Exit & Buyer Demand

Hospice Valuation amid Fraud Crackdowns, Shutdowns & Policy Shifts: What Owners Need to Know

How to Value and Sell a Home Care Business in 2026